Ivosidenib (IVO; AG-120) in IDH1-mutant newly-diagnosed acute myeloid lukemia (ND AML): Updated results from a phase 1 study Meeting Abstract


Authors: DiNardo, C. D.; Roboz, G. J.; Stein, E. M.; de Botton, S.; Mims, A. S.; Prince, G. T.; Altman, J. K.; Arellano, M. L.; Donnellan, W.; Erba, H. P.; Mannis, G. N.; Pollyea, D. A.; Stein, A. S.; Uy, G. L.; Watts, J. M.; Fathi, A. T.; Kantarjian, H. M.; Tallman, M. S.; Choe, S.; Dai, D.; Fan, B.; Wang, H.; Zhang, V.; Yen, K. E.; Kapsalis, S. M.; Hickman, D.; Liu, H.; Agresta, S. V.; Wu, B.; Attar, E. C.; Stone, R. M.
Abstract Title: Ivosidenib (IVO; AG-120) in IDH1-mutant newly-diagnosed acute myeloid lukemia (ND AML): Updated results from a phase 1 study
Meeting Title: 7th Annual Meeting of the Society of Hematologic Oncology (SOHO 2019)
Keywords: clinical trial; aml; acute myeloid leukemia; mutation analysis; newly diagnosed; ivosidenib
Journal Title: Clinical Lymphoma, Myeloma and Leukemia
Volume: 19
Issue: Suppl. 1
Meeting Dates: 2019 Sep 11-14
Meeting Location: Houston, TX
ISSN: 2152-2650
Publisher: Elsevier Inc.  
Date Published: 2019-09-01
Start Page: S220
Language: English
ACCESSION: WOS:000483480700135
DOI: 10.1016/j.clml.2019.07.094
PROVIDER: wos
Notes: Meeting Abstract: AML-208 -- Source: Wos
Altmetric Score
MSK Authors
  1. Eytan Moshe Stein
    134 Stein
  2. Martin Stuart Tallman
    461 Tallman